department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

NOVARTIS AG ($NVS) · pipeline · pharmadog

← back to NOVARTIS AG

Pipeline · $NVS

71 products

Marketedribociclib succinateKisqali (ribociclib succinate)Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)MarketedsecukinumabCosentyx (secukinumab)Hidradenitis Suppurativa Marketedsiponimod fumarateMayzent (siponimod fumarate)Relapsing Remitting Multiple Sclerosis (RRMS)MarketedtisagenlecleucelKymriah (tisagenlecleucel)B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)MarketedtriclabendazoleEgaten (triclabendazole)Helminthiasis (Parasitic Worm Infestation)Phase 3abelacimababelacimab [INN]Ischemic Stroke Phase 3brolucizumabBeovu (brolucizumab)Proliferative Diabetic Retinopathy (PDR)Phase 3dabrafenib mesylateTafinlar (dabrafenib mesylate)High-Grade Glioma Phase 3ianalumabIdiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)Phase 3pelabresibChronic Idiopathic Myelofibrosis (Primary Myelofibrosis)Phase 3spartalizumabPancreatic Cancer Phase 3votoplamHuntington Disease Phase 2(ganaplacide + lumefantrine)(ganaplacide [INN] + lumefantrine)Malaria Phase 2AAA-614Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)Phase 2AVRRD-04Cystinosis Phase 2LB-2102Neuroendocrine Carcinoma Phase 2LXE-408Leishmaniasis Phase 2PKN-605Atrial Fibrillation Phase 2XmAb bispecific antibodyUnspecified Cancer Phase 2cipargamincipargamin [INN]Malaria Phase 2trametinib dimethyl sulfoxideMekinist (trametinib dimethyl sulfoxide)Malignant Glioma Phase 2tulmimetostatEndometrial Cancer Phase 1CALY-002Eosinophilic Esophagitis Phase 1MCM-998Multiple Myeloma (Kahler Disease)Phase 1MRT-6160Axial Spondyloarthritis Phase 1farabursen sodiumPolycystic Kidney Disease Phase 1siremadlin succinateAcute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)PreclinicalVV-169Refractory Multiple Myeloma GLEEVECGLEEVEC (IMATINIB MESYLATE)1 INDICATIONS AND USAGE Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interf LEQVIOLEQVIO (INCLISIRAN SODIUM)1 INDICATIONS AND USAGE LEQVIO ® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). LEQVIO is a small interfering RNA (siRNA) directed to proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. ( 1 ) adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). ( 1 ) pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). ( 1 )

← prevpage 2 of 3next →